Assessment of the application for renewal of authorisation of pyridoxine hydrochloride (vitamin B6) as a feed additive for all animal species. (13th November 2020)

• Record Type: Journal Article
• Authors: Bampidis, Vasileios; Azimonti, Giovanna; Bastos, Maria de Lourdes; Christensen, Henrik; Dusemund, Birgit; Fašmon Durjava, Mojca; Kouba, Maryline; López‐Alonso, Marta; López Puente, Secundino; Marcon, Francesca; Mayo, Baltasar; Pechová, Alena; Petkova, Mariana; Ramos, Fernando; Sanz, Yolanda; Villa, Roberto Edoardo; Woutersen, Ruud; Anguita, Montserrat; Galobart, Jaume; Holczknecht, Orsolya; Tarrés‐Call, Jordi; Pettenati, Elisa; Pizzo, Fabiola; Manini, Paola
• Is Part Of: EFSA journal. Volume 18:Number 11(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-11-13
• Subjects: nutritional additive -- vitamin B6 -- pyridoxine hydrochloride -- renewal -- safety; Food -- Europe -- Safety measures -- Periodicals; Food Safety; Food -- Safety measures; Europe; Periodicals; Periodicals; Fulltext; Government Publications, International; Internet Resources; Periodicals; Periodicals; 363.19209405
• DOI: 10.2903/j.efsa.2020.6289
• Languages: English
• ISSNs: 1831-4732

Abstract

Abstract: Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the assessment of the application for renewal of authorisation of pyridoxine hydrochloride (vitamin B6 ) produced by chemical synthesis as a feed additive for all animal species. The applicant has provided data demonstrating that the additive in the market complies with the conditions of the authorisation. The FEEDAP Panel confirms that the use of pyridoxine hydrochloride under the current authorised conditions of use is safe for the target species, the consumers and the environment. Pyridoxine hydrochloride is non‐irritant to skin and eyes and is not a skin sensitiser. It may cause photosensitisation. In the absence of inhalation toxicity studies, adverse effects in the respiratory tract cannot be fully excluded. There is no need for assessing the efficacy of the additive in the context of the renewal of the authorisation.